SciBase receives additional Castle Biosciences order, expands collaboration

• SciBase received an additional order from Castle Biosciences to accelerate an ongoing atopic dermatitis relapse-prediction study.
• Order also covers preparations for a second clinical study under the 2025 collaboration and license agreement.
• Deliveries are expected to start in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20260908:BIT:7802:0) on September 08, 2026, and is solely responsible for the information contained therein.